Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory

Haemophilia

Volumn 19, Issue 3, 2013, Pages

  Cauchie, M ^a   Toelen, J ^a   Peerlinck, K ^a   Jacquemin, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Factor VIII; FVIII chromogenic substrate assay; FVIII one stage assay; Haemophilia A; Recombinant FVIII; Refacto AF Laboratory Standard

Indexed keywords

CHROMOGENIC SUBSTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACCURACY; ARTICLE; CALIBRATION; CASE REPORT; CHROMOGENIC ASSAY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN DOMAIN; QUANTITATIVE ASSAY; STANDARD;

CALIBRATION; CHROMOGENIC COMPOUNDS; ENZYME ASSAYS; FACTOR VIII; HEMOPHILIA A; HUMANS; LABORATORIES; RECOMBINANT PROTEINS; REFERENCE STANDARDS;

EID: 84876805295     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12093     Document Type: Article

References (12)

1. Lusher JM, Hillman-Wiseman C, Simpson P, Hurst D. Plasma FVIII levels measured after infusion of recombinant FVIII (rFVIII) vary significantly with different assay methods (will the real FVIII please stand up!). Blood 1995; 86(Suppl. 1): 192a abstract 755.
2. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
3. Lee CA, Owens D, Bray G et al. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
4. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8.
5. Ingerslev J, Jankowski MA, Weston SB. ReFacto field study participants. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623-8.
6. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
7. Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010; 16: 717-25.
8. Pouplard C, Caron C, Aillaud MF et al. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay. Haemophilia 2011; 17: e958-62.
9. Nougier C, Sobas F, Nguyen TK, Carage ML, Lienhart A, Négrier C. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay. Blood Coagul Fibrinolysis 2011; 22: 151-4.
10. Lattes S, Appert-Flory A, Fischer F, Jambou D, Toulon P. Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run. Haemophilia 2011; 17: 139-42.
11. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A. ReFacto-AICE Study Group. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003; 1: 2283-9.
12. Santoro C, Iorio A, Ferrante F et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779-87.